Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry
Abstract
Background
Left ventricular (LV) recovery in takotsubo syndrome (TTS) occurs over a wide‐ranging interval, varying from hours to weeks. We sought to investigate the clinical predictors and prognostic impact of recovery time for TTS patients.
Methods and Results
TTS patients from the International Takotsubo Registry were included in this study. Cut‐off for early LV recovery was determined to be 10 days after the acute event. Multivariable logistic regression was used to assess factors associated with the absence of early recovery. In‐hospital outcomes and 1‐year mortality were compared for patients with versus without early recovery. We analyzed 406 patients with comprehensive and serial imaging data regarding time to recovery. Of these, 191 (47.0%) had early LV recovery and 215 (53.0%) demonstrated late LV improvement. Patients without early recovery were more often male (12.6% versus 5.2%; P=0.011) and presented more frequently with typical TTS (76.3% versus 67.0%, P=0.040). Cardiac and inflammatory markers were higher in patients without early recovery than in those with early recovery. Patients without early recovery showed unfavorable 1‐year outcome compared with patients with early recovery (P=0.003). On multiple logistic regression, male sex, LV ejection fraction <45%, and acute neurologic disorders were associated with the absence of early recovery.
Conclusions
TTS patients without early LV recovery have different clinical characteristics and less favorable 1‐year outcome compared with patients with early recovery. The factors associated with the absence of early recovery included male sex, reduced LV ejection fraction, and acute neurologic events.
Clinical Trial Registration
Clinical Perspective
What Is New?
•
Left ventricular recovery in takotsubo syndrome varies from days to weeks.
•
Patients with early left ventricular recovery have a different clinical phenotype and more favorable outcomes compared with patients without early recovery.
•
Factors associated with absence of early recovery were male sex, reduced left ventricular ejection fraction, and acute neurologic events.
What Are the Clinical Implications?
•
The findings of this study highlight that takotsubo syndrome patients without early recovery have worse outcomes compared with patients with early recovery and thus should be monitored closely.
•
Prospective studies are needed to unravel the pathophysiological mechanisms of left ventricular recovery in patients with takotsubo syndrome.
Introduction
Takotsubo syndrome (TTS) is an acute heart failure syndrome characterized by left ventricular (LV) dysfunction and peculiar patterns of wall motion abnormalities (WMA).1, 2, 3, 4 Although this condition typically affects postmenopausal women and is often preceded by emotional or physical triggers, recent studies have demonstrated that TTS is more heterogeneous than previously thought.1, 5, 6, 7, 8, 9 Several studies have shown that TTS, which has typically been considered a benign disease, may represent a serious illness with mortality rates comparable to acute coronary syndrome in the acute phase and with a high rate of adverse events at long‐term follow‐up.1, 10, 11
Despite the recent progress in understanding TTS, many uncertainties remain. Recovery from LV dysfunction is a pivotal defining characteristic of TTS. However, the pathophysiological mechanisms underlying the LV dysfunction are still unclear and the clinical aspects of recovery have scarcely been investigated. Previous studies have shown that most patients with TTS recover from LV dysfunction within 1 to 6 months, but wide interindividual variation in the duration of the recovery process has been reported.1, 12, 13, 14 Moreover, the clinical implications of recovery time in TTS are also uncertain. First, it is unclear whether the differences in the duration of recovery affect outcomes of TTS patients. Second, the specific clinical parameters that influence or predict the duration of the LV recovery process are unknown. Finally, patients with higher risk of late resolution of WMA cannot currently be identified during the acute phase. This last issue might be of particular importance because this patient population may require longer monitoring and supportive therapy to improve outcomes.
In this analysis, we aimed to assess the clinical features of TTS patients without early resolution of WMA and to compare their outcomes to those of patients with early resolution of WMA. Furthermore, clinical parameters associated with the absence of early recovery were investigated.
Methods
Study Population
Data were collected from the InterTAK Registry (International Takotsubo Registry, www.takotsubo-registry.com),15 which is a multicenter, prospective, and retrospective observational registry established at the University Hospital Zurich in 2011. The authors declare that all supporting data are available within the article. The study design, methods, and objectives were reported recently in a previous study.1 TTS was defined based on InterTAK Diagnostic Criteria.3 Medical records were reviewed by investigators at the University Hospital Zurich. Uncertain cases were reviewed by core team members at the University Hospital Zurich, and the decision for inclusion or exclusion was reached by consensus. Follow‐up information was obtained from medical records, telephone interviews, or clinical visits. The study protocol was reviewed by the respective local ethics committee or investigational review board at each collaboration site. Given the partly retrospective nature of the study, ethics committees of most study centers waived the need for informed consent. At centers for which the ethics committees or investigational review boards required informed consent or from which patients were included prospectively, formal written consent was obtained from patients or surrogates.
Recovery Analysis
Recovery was defined as complete resolution of WMA in follow‐up echocardiography or cardiac magnetic resonance imaging compared with the initial echocardiogram or ventriculogram. Patients were divided into 2 groups based on the presence or absence of WMA recovery within 10 days after TTS onset. Accordingly, patients who demonstrated recovery within 10 days of the index event were assigned to the early recovery group, whereas patients with persistent WMA after 10 days were allocated to the group without early recovery (Figure 1). These groups were compared to explore the differences in clinical profiles and outcomes. Patients who could not be categorized in one of the groups (eg, patients with documentation of resolution of WMA after several weeks without recovery information at previous time points) were not included in the analysis.
![image](/cms/10.1161/JAHA.118.011194/asset/3edc99bb-76ba-499b-9a44-1050520dab54/assets/graphic/jah34454-fig-0001.png)
Study Outcomes
Data regarding in‐hospital complications (cardiogenic shock, death, ventricular thrombus) and their management (invasive or noninvasive ventilation, catecholamine administration) were recorded. The main outcome measure of this analysis was 1‐year mortality. Patients whose follow‐up was shorter than 10 days or who died during the first 10 days after TTS event were excluded from the analysis. Consequently, the qualifying events for outcome analysis were recorded from the 11th day after admission. Factors associated with the absence of early recovery in TTS patients were also investigated.
Statistical Analyses
Continuous variables are reported as mean±SD or median with interquartile range, whereas categorical variables are presented as frequency with percentage. Continuous variables were compared using the Mann–Whitney U test, whereas the Pearson χ2 test (or Fisher exact test, as appropriate) was used for the comparison of categorical variables. Survival estimates were assessed using Kaplan–Meier curves, and group differences were evaluated with the log‐rank test. Multivariable logistic regression was used to identify the parameters associated with the absence of early recovery in TTS patients. Covariates with P<0.05 at baseline comparison between the groups (with versus without early recovery) were included in the multivariable model; a multiple regression imputation analysis was then performed to account for missing values. The cut‐off for statistical significance was set at a 2‐sided P value <0.05. Odds ratios are reported with the respective 95% CIs. Analyses were computed with SPSS statistical software, version 23.0 (IBM Corp). Figures were created with Prism 7 software (GraphPad).
Results
Patient Characteristics
Of 406 patients, 191 (47%) were assigned to the early recovery group (Figure 1). In the early recovery group, median time to WMA resolution was 5 days (interquartile range: 3–7 days). In the group without early recovery, follow‐up imaging assessment was performed at a median of 30 days (interquartile range: 14–57 days). The baseline features of the 2 study groups are shown in Table. Patients without early resolution of WMA were more often male (12.6% versus 5.2%, P=0.011) and were more likely to have physical triggers (46.5% versus 35.1%, P=0.020) compared with patients with early resolution of WMA. Patients without early resolution of WMA had higher prevalence of comorbidities, particularly acute neurologic disorders, such as intracranial bleeding, stroke or seizure (9.6% versus 1.7%, P=0.001), and malignancies (22.1% versus 12.2%, P=0.010). TTS patients without early resolution of WMA presented with typical TTS more frequently (76.3% versus 67.0%, P=0.040) and had lower LV ejection fraction (LVEF) on admission (37.3±10.7% versus 43.7±11.9%, P<0.001). Moreover, patients without early resolution of WMA presented with higher values of troponin, CRP (C‐reactive protein), and white blood cell counts on admission.
Characteristic | TTS With Early Recovery (n=191) | TTS Without Early Recovery (n=215) | P Value |
---|---|---|---|
Demographics | |||
Female sex | 181/191 (94.8) | 188/369 (87.4) | 0.011 |
Age, y | 64.2±13.0 (n=191) | 66.1±12.8 (n=215) | 0.13 |
Symptoms and triggers | |||
Chest pain | 131/175 (74.9) | 127/192 (66.1) | 0.07 |
Dyspnea | 90/175 (51.4) | 98/195 (50.3) | 0.82 |
Physical trigger | 67/191 (35.1) | 100/215 (46.5) | 0.020 |
Emotional trigger | 60/191 (31.4) | 62/215 (28.8) | 0.57 |
Cardiac biomarkers | |||
Troponin on admission—factor increase in ULN* | 5.96 (1.89–13.15); n=156 | 7.29 (2.00–23.54); n=168 | 0.040 |
Creatine kinase on admission—factor increase in ULN | 0.83 (0.52–1.20); n=148 | 0.84 (0.48–1.43); n=141 | 0.92 |
BNP on admission—factor increase in ULN† | 4.97 (2.44–12.80); n=57 | 9.87 (2.74–27.07); n=65 | 0.12 |
Inflammatory markers | |||
CRP on admission, mg/L | 3.35 (1.03–8.98); n=132 | 5.10 (2.30–18.40); n=125 | 0.005 |
WBC on admission, 103/μL | 9.00 (7.11–11.65); n=169 | 10.40 (7.67–12.65); n=185 | 0.010 |
ECG on admission | |||
Sinus rhythm | 161/169 (95.3) | 172/185 (93.0) | 0.36 |
Atrial fibrillation | 7/169 (4.1) | 12/185 (6.5) | 0.33 |
AV block (I, II, or III) | 5/169 (3.0) | 17/185 (9.2) | 0.020 |
ST‐segment elevation | 63/169 (37.3) | 72/185 (38.9) | 0.75 |
ST‐segment depression | 9/169 (5.3) | 14/185 (7.6) | 0.39 |
T‐wave inversion | 72/169 (42.6) | 79/185 (42.7) | 0.99 |
QTc, ms | 457.4±46.8 (n=140) | 459.8±43.7 (n=151) | 0.64 |
Imaging and hemodynamic findings | |||
Apical type | 128/191 (67.0) | 164/215 (76.3) | 0.040 |
LV ejection fraction, %‡ | 43.7±11.9 (n=169) | 37.3±10.7 (n=191) | <0.001 |
LV end‐diastolic pressure, mm Hg | 21.3±8.9 (n=114) | 22.2±7.6 (n=114) | 0.40 |
Heart rate, beats/min | 87.7±22.5 (n=151) | 91.3±23.3 (n=162) | 0.17 |
Systolic blood pressure, mm Hg | 131.3±33.3 (n=157) | 131.8±30.0 (n=166) | 0.67 |
Cardiovascular risk factors/history | |||
Hypertension | 124/188 (66.0) | 133/210 (63.3) | 0.56 |
Diabetes mellitus | 29/186 (15.6) | 29/210 (13.8) | 0.62 |
Hypercholesterolemia | 58/183 (31.7) | 82/207 (39.6) | 0.10 |
Coexisting medical condition | |||
Acute intracranial bleeding, stroke/TIA, seizure | 3/173 (1.7) | 20/208 (9.6) | 0.001 |
Past or chronic neurologic disorders | 24/172 (14.0) | 46/205 (22.4) | 0.035 |
Acute psychiatric disorders | 18/173 (10.4) | 19/208 (9.1) | 0.68 |
Past or chronic psychiatric disorders | 47/172 (27.3) | 53/205 (25.9) | 0.75 |
Cancer (total) | 22/181 (12.2) | 44/199 (22.1) | 0.010 |
Medication on admission | |||
ACE inhibitor or ARB | 52/156 (33.3) | 60/163 (36.8) | 0.52 |
Beta‐blocker | 59/156 (37.8) | 47/164 (28.7) | 0.08 |
Calcium‐channel antagonist | 9/156 (5.8) | 8/163 (4.9) | 0.73 |
Statin | 23/156 (14.7) | 25/163 (15.3) | 0.88 |
Aspirin | 50/156 (32.1) | 49/163 (30.1) | 0.70 |
In‐hospital complications and management | |||
Cardiogenic shock | 17/191 (8.9) | 32/214 (15.0) | 0.06 |
Death | 5/191 (2.6) | 7/215 (3.3) | 0.71 |
Catecholamine use | 21/191 (11.0) | 36/215 (16.7) | 0.10 |
Ventricular thrombus | 0/189 (0.0) | 6/210 (2.9) | 0.030 |
Invasive or noninvasive ventilation | 28/191 (14.7) | 56/215 (26.0) | 0.005 |
Values are mean ± SD, no./total n (%), or median (interquartile range). ACE indicates angiotensin‐converting‐enzyme; ARB, angiotensin‐receptor blocker; AV block, atrioventricular block; BNP, brain natriuretic peptide; CRP, C‐reactive protein; IQR, interquartile range; LV, left ventricular; QTc, QT interval corrected for heart rate; TIA, transient ischemic attack; TTS, takotsubo syndrome; ULN, upper limit of the normal range; WBC white blood cell count.
*
Including ULNs for troponin T, high‐sensitivity troponin T, and troponin I.
†
Including ULNs for brain natiuretic peptide and the N‐terminal of prohormone brain natiuretic peptide.
‡
LV ejection fraction (%): information from catheterization or echocardiography, if both available: catheterization.
Outcomes
Patients without early resolution of WMA required invasive and noninvasive ventilation more frequently compared with patients with early resolution of WMA (26.0% versus 14.7%, P=0.005). Moreover, a trend toward a higher rate of cardiogenic shock was observed in TTS patients without early resolution of WMA (15.0% versus 8.9%, P=0.06). Interestingly, a significantly higher prevalence of ventricular thrombus was shown in TTS patients without early resolution of WMA (2.9% versus 0.0%, P=0.030). In addition, inotropic agents were more frequently used in patients in the group without early recovery, although the difference was not significant (16.7% versus 11.0%, P=0.10). Patients without early resolution of WMA had a significantly higher mortality rate at 1‐year compared with patients with early recovery of WMA (7.4% versus 1.3%, P=0.003; Figure 2).
![image](/cms/10.1161/JAHA.118.011194/asset/d3c3f916-82aa-4060-a9c1-c464cdb7fb07/assets/graphic/jah34454-fig-0002.png)
Factors Associated With Absence of Early Recovery
Multivariable logistic regression analysis was conducted, including covariates with significant differences (P<0.05) at baseline between patients with and without early recovery (Figure 3). We identified male sex, LVEF <45%, and a composite of acute neurologic events as factors associated with the absence of early recovery. The results remained similar after excluding the composite of acute neurologic disorders from the multivariable model (Figure S1).
![image](/cms/10.1161/JAHA.118.011194/asset/d0b81a4b-a817-4009-b73a-acaf20837132/assets/graphic/jah34454-fig-0003.png)
Discussion
To our knowledge, this study is the largest investigating the predictors and prognostic impact of absence of early recovery in TTS. The study had 3 main findings: (1) patients with longer recovery time for WMA were more frequently male, had a higher prevalence of physical triggers initiating TTS, presented more commonly with typical TTS (apical ballooning), and presented with lower LVEF and higher troponin and inflammatory marker levels on admission; (2) male sex, LVEF <45%, and concomitant acute neurologic events were associated with the absence of early recovery in TTS; and (3) delayed resolution of WMA was associated with higher mortality at 1‐year.
On multivariable analysis, male sex, depressed LVEF, and acute neurologic comorbidities were identified as risk factors associated with the absence of early recovery. These results are clinically important because patients with these characteristics should be monitored closely after hospitalization, given the higher risk of potential clinical complications. A previous study by Shiomura et al reported brain natriuretic peptide levels, body mass index, and nonuse of calcium channel blockers as independent predictors for delayed LV recovery. However, the difference in their findings may be due to the small size of that study (n=60).16
Rates of cardiogenic shock and invasive or noninvasive ventilation were higher in the group without early recovery. In addition, patients with longer WMA recovery duration appeared to be more susceptible to ventricular thrombus formation, most likely because of the extent of myocardial involvement and longer impairment of LV function. Nevertheless, a complicated acute course of the disease might adversely impact the recovery rate. The fact that those with prolonged recovery presented with higher troponin levels and lower LVEF supports this interpretation. It may just take more time to recover from a severely depressed LVEF than from a mild impairment of pump function.
Patients without early resolution of WMA had significantly elevated inflammatory markers, but these findings were not significant on multivariable analysis. Higher levels of inflammatory markers may have affected the outcome; however, inflammatory response could be due to the preexisting comorbidities in these patients. Indeed, TTS patients with longer recovery from WMA more commonly experienced acute neurologic conditions, which are known to be associated with elevated CRP levels. Similarly, it is known that neurologic disorders may lead to profound cardiac damage with pathological changes including contraction band necrosis, found in autopsied patients with sudden unexpected death in epilepsy as well as in TTS patients.17, 18 In this regard, TTS patients with acute neurologic comorbidities might have more severe “neurocardiac damage” with longer LV recovery times.
Schwarz et al recently reported persistent WMA at 4‐month follow‐up despite overall normalization of LVEF in some TTS patients.19 The researchers noted subtle cardiac deformations and impaired contraction as assessed by LV twist and strain analysis. Moreover, a previous study by Scally et al reported impaired cardiac energetic status and the development of a heart failure phenotype on long‐term follow‐up in some TTS patients.20 These results suggest the occurrence of prolonged impairment of cardiac function despite visual assessment suggestive of recovery of WMA and LVEF improvement. This surprising persistence of cardiac functional impairments in TTS should be evaluated further; the issue of “incomplete recovery” is a relatively new concept, and its mechanisms and clinical implications are unknown.20, 21
We sought to provide parameters that are relatively easy to obtain in daily clinical practice to detect TTS patients with potentially longer recovery times for WMA. Our results suggest the importance of clinical vigilance in TTS patients, particularly those with prolonged resolution of WMA. Future studies evaluating therapeutic strategies are needed to accelerate LV recovery and to improve long‐term prognosis in TTS patients.
Study Limitations
This study is partly retrospective in nature and is based on an international multicenter registry. Moreover, the dichotomous classification of those with and without early recovery may influence our results because a priori imaging time points were not selected. The vast majority of imaging studies were performed by echocardiography; cardiac magnetic resonance imaging was not performed in all patients because data went back to 1998, when cardiac magnetic resonance imaging was not broadly and systematically available.22 The multivariable analysis did not demonstrate an association between physical triggers and the absence of early recovery, likely because of the sample size of the study. Multivariable logistic regression analysis was used to investigate the covariates associated with the absence of early recovery, given the retrospective limitation of assessing the exact time to recovery. Furthermore, multivariable assessment of survival was not performed because of the limited number of events at follow‐up, which prevented the establishment of an accurate and reliable model.
Conclusions
This study offers new insights into the clinical impact of LV recovery time in TTS patients. Patients without early LV recovery have higher prevalence of in‐hospital complications and higher mortality and should be monitored closely. Further prospective studies are needed to uncover the actual mechanism underlying LV recovery in TTS.
Sources of Funding
Christian Templin was supported by the H.H. Sheikh Khalifa bin Hamad Al‐Thani Research Programme and the Swiss Heart Foundation. The InterTAK Registry is supported by the Biss Davies Charitable Trust.
Disclosures
None.
Supplemental Material
Figure S1. Multivariate logistic regression.
- Download
- 92.73 KB
References
1.
Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun‐Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–938.
2.
Ghadri JR, Cammann VL, Napp LC, Jurisic S, Diekmann J, Bataiosu DR, Seifert B, Jaguszewski M, Sarcon A, Neumann CA, Geyer V, Prasad A, Bax JJ, Ruschitzka F, Luscher TF, Templin C; International Takotsubo (InterTAK) Registry . Differences in the clinical profile and outcomes of typical and atypical takotsubo syndrome: data from the International Takotsubo Registry. JAMA Cardiol. 2016;1:335–340.
3.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, S YH, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C. International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J. 2018;39:2032–2046.
4.
Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, S YH, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C. International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management. Eur Heart J. 2018;39:2047–2062.
5.
Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako‐tsubo) cardiomyopathy. J Am Coll Cardiol. 2010;55:333–341.
6.
Schneider B, Athanasiadis A, Schwab J, Pistner W, Gottwald U, Schoeller R, Toepel W, Winter KD, Stellbrink C, Muller‐Honold T, Wegner C, Sechtem U. Complications in the clinical course of tako‐tsubo cardiomyopathy. Int J Cardiol. 2014;176:199–205.
7.
Schlossbauer SA, Ghadri JR, Scherff F, Templin C. The challenge of Takotsubo syndrome: heterogeneity of clinical features. Swiss Med Wkly. 2017;147:w14490.
8.
Kato K, Lyon AR, Ghadri JR, Templin C. Takotsubo syndrome: aetiology, presentation and treatment. Heart. 2017;103:1461–1469.
9.
Ghadri JR, Kato K, Cammann VL, Gili S, Jurisic S, Di Vece D, Candreva A, Ding KJ, Micek J, Szawan KA, Bacchi B, Bianchi R, Levinson RA, Wischnewsky M, Seifert B, Schlossbauer SA, Citro R, Bossone E, Munzel T, Knorr M, Heiner S, D'Ascenzo F, Franke J, Sarcon A, Napp LC, Jaguszewski M, Noutsias M, Katus HA, Burgdorf C, Schunkert H, Thiele H, Bauersachs J, Tschope C, Pieske BM, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun‐Dullaeus RC, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Empen K, Felix SB, Delmas C, Lairez O, El‐Battrawy I, Akin I, Borggrefe M, Horowitz J, Kozel M, Tousek P, Widimsky P, Gilyarova E, Shilova A, Gilyarov M, Winchester DE, Ukena C, Bax JJ, Prasad A, Bohm M, Luscher TF, Ruschitzka F, Templin C. Long‐term prognosis of patients with Takotsubo syndrome. J Am Coll Cardiol. 2018;72:874–882.
10.
Tornvall P, Collste O, Ehrenborg E, Jarnbert‐Petterson H. A case‐control study of risk markers and mortality in takotsubo stress cardiomyopathy. J Am Coll Cardiol. 2016;67:1931–1936.
11.
Redfors B, Vedad R, Angeras O, Ramunddal T, Petursson P, Haraldsson I, Ali A, Dworeck C, Odenstedt J, Ioaness D, Libungan B, Shao Y, Albertsson P, Stone GW, Omerovic E. Mortality in Takotsubo syndrome is similar to mortality in myocardial infarction—a report from the SWEDEHEART registry. Int J Cardiol. 2015;185:282–289.
12.
Tsuchihashi K, Ueshima K, Uchida T, Oh‐mura N, Kimura K, Owa M, Yoshiyama M, Miyazaki S, Haze K, Ogawa H, Honda T, Hase M, Kai R, Morii I; Angina Pectoris‐Myocardial Infarction Investigations in Japan . Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris‐Myocardial Infarction Investigations in Japan. J Am Coll Cardiol. 2001;38:11–18.
13.
Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four‐year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007;50:448–452.
14.
Kumar S, Mostow N, Grimm RA. Quick resolution of takotsubo cardiomyopathy: a brief review. Echocardiography. 2008;25:1117–1120.
15.
Ghadri JR, Cammann VL, Templin C. The International Takotsubo Registry: rationale, design, objectives, and first results. Heart Fail Clin. 2016;12:597–603.
16.
Shiomura R, Nakamura S, Takano H, Kato K, Inui K, Kubota Y, Komiyama H, Murai K, Asai K, Shimizu W. Impact of brain natriuretic peptide, calcium channel blockers, and body mass index on recovery time from left ventricular systolic dysfunction in patients with takotsubo cardiomyopathy. Am J Cardiol. 2015;116:515–519.
17.
Natelson BH, Suarez RV, Terrence CF, Turizo R. Patients with epilepsy who die suddenly have cardiac disease. Arch Neurol. 1998;55:857–860.
18.
Yoshida T, Hibino T, Kako N, Murai S, Oguri M, Kato K, Yajima K, Ohte N, Yokoi K, Kimura G. A pathophysiologic study of tako‐tsubo cardiomyopathy with F‐18 fluorodeoxyglucose positron emission tomography. Eur Heart J. 2007;28:2598–2604.
19.
Schwarz K, Ahearn T, Srinivasan J, Neil CJ, Scally C, Rudd A, Jagpal B, Frenneaux MP, Pislaru C, Horowitz JD, Dawson DK. Alterations in cardiac deformation, timing of contraction and relaxation, and early myocardial fibrosis accompany the apparent recovery of acute stress‐induced (takotsubo) cardiomyopathy: an end to the concept of transience. J Am Soc Echocardiogr. 2017;30:745–755.
20.
Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, Broadhurst P, Newby DE, Henning A, Dawson DK. Persistent long‐term structural, functional, and metabolic changes after stress‐induced (takotsubo) cardiomyopathy. Circulation. 2018;137:1039–1048.
21.
Singh K. Tako‐Tsubo syndrome: issue of incomplete recovery and recurrence. Eur J Heart Fail. 2016;18:1408–1410.
22.
Templin C, Ghadri JR, Napp LC. Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:2689–2691.
Information & Authors
Information
Published In
Copyright
© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
History
Received: 2 February 2019
Accepted: 30 July 2019
Published online: 1 November 2019
Published in print: 5 November 2019
Keywords
Subjects
Notes
(J Am Heart Assoc. 2019;8:e011194. https://doi.org/10.1161/JAHA.118.011194.)
Authors
Funding Information
H.H. Sheikh Khalifa bin Hamad Al‐Thani Research Program
Biss Davies Charitable Trust
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Time Course of Left Ventricular Strain Assessment via Cardiovascular Magnetic Resonance Myocardial Feature Tracking in Takotsubo Syndrome, Journal of Clinical Medicine, 13, 11, (3238), (2024).https://doi.org/10.3390/jcm13113238
- Takotsubo Syndrome or Peripartum Cardiomyopathy? Depends on Who You Are Talking to, Behavioral Sciences, 14, 9, (777), (2024).https://doi.org/10.3390/bs14090777
- Transient Left Ventricular Dysfunction from Cardiomyopathies to Myocardial Viability: When and Why Cardiac Function Recovers, Biomedicines, 12, 5, (1051), (2024).https://doi.org/10.3390/biomedicines12051051
- Takotsubo Cardiomyopathy: Patients Characteristics, Mortality, and Clinical Significance of Left Ventricular Outflow Tract Gradient, Retrospective Study, Cardiology Research and Practice, 2024, 1, (2024).https://doi.org/10.1155/2024/5549795
- Rationale and design of the beta-blockers in tako-tsubo syndrome study: a randomized clinical trial (β-Tako), Revista Española de Cardiología (English Edition), (2024).https://doi.org/10.1016/j.rec.2024.12.006
- Levosimendan: current and possible areas of clinical application: A review, Annals of Critical Care, 3, (122-136), (2023).https://doi.org/10.21320/1818-474X-2023-3-122-136
- The Efficiency of Attentional Networks in Takostubo Syndrome: A Study With the Attentional Network Task for Interaction, Journal of Attention Disorders, 28, 4, (469-479), (2023).https://doi.org/10.1177/10870547231215517
- Takotsubo syndrome: getting closer to its causes, Cardiovascular Research, 119, 7, (1480-1494), (2023).https://doi.org/10.1093/cvr/cvad053
- Takotsubo syndrome: We are still “halfway”. A complex heart-brain duality?, Revista Portuguesa de Cardiologia, 42, 3, (247-249), (2023).https://doi.org/10.1016/j.repc.2023.01.004
- Comprehensive invasive evaluation of coronary microcirculation in patients with Takotsubo syndrome, Atherosclerosis, 385, (117332), (2023).https://doi.org/10.1016/j.atherosclerosis.2023.117332
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.